Training and Education
Cutting-edge product for stem cell research and human embryo modelling
Amsbio reports that its iMatrix-511 recombinant laminin product has been cited in a recent paper** from researchers at the Stanford University School of Medicine, Stanford, CA, USA as a pivotal tool for stem cell culture and blastoid formation.
This groundbreaking...
Circulating Biomarkers of Cardiac Fibrosis: From Bench to Bedside
Heart disease remains one of the leading health challenges of the 21st century, with modern lifestyles only amplifying its global impact. Among its many contributors, cardiac fibrosis plays a crucial yet sometimes overlooked role (1). Detecting and managing fibrosis early...
Gentle and rapid detachment of even delicate adherent cells
Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels.
Widely cited in recent published papers1, 2, 3, 4 - Detachin™ is proven to quickly deliver gentle...
Efficient extraction of proteins from bacterial cells.
SoluLyse™ from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells.
Based upon a proprietary non-ionic detergent formulation, with the SoluLyse™ reagent there is no need for...
The National Trust’s Plant Conservation Centre is Protecting Rare Plants with a Monmouth Scientific Class 2 Biological Safety Cabinet.
Protecting the UK’s rare and endangered plants requires precision, expertise, and the right technology. At the National Trust’s Plant Conservation Centre (PCC), staff are using a Monmouth Scientific Class 2 Biological Safety Cabinet to propagate delicate species in completely sterile...
Cost-effective cryopreservation without compromise
A new blog has been published by Amsbio comparing the benefits of its CELLBANKER® range of cryopreservation solutions with ‘homebrew’ cryopreservation media.
Homebrew cryopreservation media are do-it-yourself solutions, commonly using a mixture of DMSO, a serum (such as FBS), and...
The hidden danger of mycotoxins: how ELISA kits improve food safety research
Mycotoxins are toxic secondary metabolites produced by certain fungi, many of which can infect agricultural crops such as wheat, corn, and nuts. Their presence poses a significant concern for the food industry, as exposure can occur directly in plant-based...
Validated Cytokines for Organoid Culture
Amsbio has launched over a range of over 30 independently developed and manufactured organoid culture-related cytokines for researchers working with stem cells and induced pluripotent stem cells (iPSCs). This new range of cytokines is tailored for and validated in...
From litres to nanolitres: scaling dosing control from macro to micro
Precision and accuracy are essential for liquid dosing applications to ensure quality and safety. While these factors are vital at the micro level, macro scale applications, involving litres of product, can also make significant efficiency gains by optimising dosing...
Why life sciences must build Recall Ready systems now
From paracetamol contamination to failing defibrillators, recent recall events show how fragile response mechanisms remain. Pete Gillett, founder of Marketpoint Recall, explores why life sciences firms must modernise recall operations before regulatory, financial and reputational costs spiral further.
In mid‑2025,...
Reprocell Europe – Advancing global life sciences from NETPark
Reprocell Europe, part of the global life sciences company Reprocell Inc. (Japan), is a leading example of high-tech inward investment operating successfully from the North East Technology Park (NETPark) in County Durham.
The company’s site within the science park’s Plexus...
Beyond Reach: Enabling the New Era of Digital-First Pharma
When the internet became part of everyday life, it reshaped how people communicated, learned, and worked. Today, we face a similar shift: Gen Alpha is the first generation to grow up with AI as a native presence.
For pharma, this...
Serious disease research takes big step forward in UK
Insmed recently opened a new R&D facility in Cambridge focused on synthetic rescue for serious diseases. Dr Tom Heightman, SVP of Research at the global biopharmaceutical, explains why the company is focused on UK expansion.
Insmed specialises in striving to...
Global warming ‘accelerates antibiotic resistance in soils’
An international study involving researchers from Durham University reveals that climate change is accelerating the rate of development and global abundances of antibiotic resistance bacteria in soils.
The findings, published in the journal Nature Ecology & Evolution, highlight a new...
AI: reimagining AI healthcare
The UK can overcome challenges and harness AI to address the immense pressures on the NHS, says Pratik Maroo, Senior Vice President and Head – Healthcare and Life Sciences, Zensar.
The UK Prime Minister’s Plan for Change focuses on how...
How AI is driving repurposing of drugs for rare diseases
Dr Anton Yuryev, consulting director, Bioinformatics and Data Science, Elsevier, explores two case studies where researchers have used AI to find drugs that can be repurposed for rare conditions.
There are more than 300 million people worldwide living with a...
How structural biology is shaping the future of vaccines
By Professor Sir Dave Stuart FRS, Director of Life Sciences at Diamond Light Source and MRC Professor of Structural Biology at the University of Oxford.
Vaccines have saved 154 million lives in the last 50 years - that is up...
World-first transplant technology wins 2025 MacRobert Award
A University of Oxford spinout has won the £50,000 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation, for its life-saving technology that is supporting more organ transplants and helping to cut waiting lists.
OrganOx has...
Found: protein that helps cancer spread – and could stop it!
Biomedical scientists have discovered a protein called SAS-6 that controls how cells divide can stave off the spread of cancer.
SAS-6 makes cells grow more and longer cilia – tiny antennae that sense their surroundings. These cilia activate a pathway...
Rules of protein stability are a billion years old
The rules required to make proteins stable are much simpler than previously thought, according to new research.
Published in the journal Science, the study has taken an important step towards learning the rules of protein stability, which may help protein...
Spinal cord injuries healed with bioelectricity
A groundbreaking bioelectric implant has restored movement in rats after spinal cord injuries.
The breakthrough offers new hope for an effective treatment for humans suffering from loss of sensation and function due to spinal cord injury.
The implant is developed by...
Stroke AI software hailed as ‘revolutionary’
An AI software platform has tripled the number of stroke patients achieving functional independence, from 16% to 48%, according to a study by the Royal Berkshire Hospital.
Additional data from the largest real-world evaluation of stroke AI imaging showed that...
Scotland’s total body PET scanner
UK’s world-class imaging platform extends to Scotland.
Scotland’s first total-body scanner is in situ at the Royal Infirmary of Edinburgh, meaning the National PET (Positron Emission Tomography) Imaging Platform network is now operational across the whole UK.
It’s part of a...
Nanoflowers could support brain health
Novel nanomaterials may protect against neurological diseases through their antioxidant abilities.
At Texas A&M AgriLife Research, a new branch of brain science is blooming at the molecular scale – with nanoflowers.
A study published in The Journal of Biological Chemistry demonstrated...
Have we hit peak oncology? Navigating the state of cancer R&D in 2025
Recent levelling-off signals a maturing sector, says Ian Lloyd, Senior Director, Citeline.
The pharmaceutical R&D ecosystem has never been bigger. The global drug pipeline now approaches 24,713 active targets, with numbers increasing 145% from January 2010 to January 20251 – a...
Parkinson’s: How the affected side shapes disease course
A team from UNIGE and HUG has shown that the side on which the first symptoms of the disease appear – left or right – influences patients’ cognitive and emotional symptoms.
Parkinson’s disease often begins asymmetrically, affecting either the right...
3D-printed tumour models speed up cancer drug testing
Vidmantas Šakalys, CEO of Vital3D, offers insights on the potential applications of the technology and key limitations that still need to be resolved.
Rising global cancer cases and diagnostic backlogs are increasing demand for more accurate and efficient research tools....
Breakthrough glioblastoma treatments move closer
A collaborative project aims to accelerate a new approach to treat the most aggressive forms of brain cancer.
Medicines Discovery Catapult (MDC) and King’s College London (KCL) have been awarded £400k funding from The Brain Tumour Charity to develop a...
New NICE thresholds ‘good news’ for ultra-rare disease drugs
The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds it applies for drugs that qualify for their Highly Specialised Technology (HST)...
£7.5m global prize pushes for ALS drug treatment breakthrough
The Longitude Prize on ALS, a new £7.5 million global challenge prize, aims to encourage and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral sclerosis), the most common form of MND...
